TABLE 3.
Ritonavir pharmacokinetic parametersa
| Treatment | Cmax,ss (μg/ml) | Cmin,ss (μg/ml) | Tmax,ss (h) | AUC0-10 (μg · h/ml) | AUCss (μg · h/ml) |
|---|---|---|---|---|---|
| All patients (n = 19) | 0.62 (0.45, 0.86) | 0.11 (0.08, 0.15) | 1.00 (0.83-4.02) | 2.94 (2.09, 4.13) | 3.13 (2.63, 4.86) |
| APV-RTV (n = 10) | 0.95 (0.67, 1.36) | 0.15 (0.11, 0.22) | 1.50 (0.92-4.02) | 4.89 (3.72, 6.42) | 4.90 (3.73, 6.81) |
| APV-RTV-EFV (n = 7) | 0.41 (0.25, 0.66) | 0.08 (0.04, 0.14) | 2.00 (0.92-4.02) | 2.03 (1.46, 2.82) | 2.22 (1.62, 3.02) |
a
Abbreviations: APV, amprenavir; RTV, ritonavir; EFV, efavirenz. Summary statistics are given for patients who received amprenavir and ritonavir and for patients who received amprenavir and ritonavir plus efavirenz. Values are geometric means (95% confidence intervals) for all parameters except Tmax,ss, which is given as the median (range).